Last updated on September 2017

A phase 3, multi-center, randomized, placebo controlled, double-blind, study of the efficacy and safety of apremilast (CC-1004) in subjects with moderate to severe plaque psoriasis of the scalp.


Brief description of study

A phase 3, multi-center, randomized, placebo controlled, double-blind, study of the efficacy and safety of apremilast (CC-1004) in subjects with moderate to severe plaque psoriasis of the scalp.

Detailed Study Description

Otezla vs. Placebo for 16 weeks, 2:1
Open label week 16-32
4 week followup

Clinical Study Identifier: TX153238

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.